Rhythm Pharmaceuticals (RYTM) Income towards Parent Company (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Income towards Parent Company data on file, last reported at -$55.6 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$55.6 million, down 12.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$202.6 million (down 20.05% YoY), and the FY2025 annual result was -$196.5 million, up 24.58% from the prior year.
• Income towards Parent Company slipped to -$55.6 million in Q1 2026 per RYTM's latest filing, from -$47.5 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$32.3 million in Q2 2024 and troughed at -$141.4 million in Q1 2024.
• A 5-year average of -$51.7 million and a median of -$46.6 million in 2025 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company tumbled 220.07% in 2022, then jumped 64.97% in 2025.
• A 5-year view of Income towards Parent Company shows it stood at -$42.5 million in 2022, then increased by 2.02% to -$41.6 million in 2023, then slipped by 4.07% to -$43.3 million in 2024, then dropped by 9.64% to -$47.5 million in 2025, then declined by 17.12% to -$55.6 million in 2026.
• Business Quant data shows RYTM's Income towards Parent Company at -$55.6 million in Q1 2026, -$47.5 million in Q4 2025, and -$52.9 million in Q3 2025.